About Aiolos Bio
Aiolos Bio is a company based in Boston (United States) founded in 2023 by Khurem Farooq and Tony Adamis was acquired by GSK in January 2024.. Aiolos Bio has raised $245 million across 1 funding round from investors including RA Capital, GSK and Atlas Venture. Aiolos Bio operates in a competitive market with competitors including Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Kardigan, among others.
- Headquarter Boston, United States
- Founders Khurem Farooq, Tony Adamis
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$245 M (USD)
in 1 rounds
-
Latest Funding Round
$245 M (USD), Series A
Oct 24, 2023
-
Investors
RA Capital
& 5 more
-
Employee Count
Employee Count
-
Acquired by
GSK
(Jan 09, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Aiolos Bio
Aiolos Bio has successfully raised a total of $245M through 1 strategic funding round. The most recent funding activity was a Series A round of $245 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $245.0M
-
First Round
First Round
(24 Oct 2023)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - Aiolos Bio | Valuation | Atlas Venture , Bain Capital Life Sciences |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aiolos Bio
Aiolos Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, GSK and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aiolos Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aiolos Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aiolos Bio Comparisons
Competitors of Aiolos Bio
Aiolos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Kardigan, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| domain | founded_year | HQ Location |
Biotech company developing personalized medicines for cardiovascular diseases
|
|
| domain | founded_year | HQ Location |
APIs and finished dosage forms are developed and manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aiolos Bio
Frequently Asked Questions about Aiolos Bio
When was Aiolos Bio founded?
Aiolos Bio was founded in 2023.
Where is Aiolos Bio located?
Aiolos Bio is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Aiolos Bio?
Khurem Farooq is the current CEO of Aiolos Bio. They have also founded this company.
Is Aiolos Bio a funded company?
Aiolos Bio is a funded company, having raised a total of $245M across 1 funding round to date. The company's 1st funding round was a Series A of $245M, raised on Oct 24, 2023.
What does Aiolos Bio do?
Aiolos Bio is a biotech company focused on developing innovative therapies for respiratory diseases and immune conditions. They recently launched with a 245 million Series A investment to advance the development of their novel Phase 2-ready TSLP antibody.
Who are the top competitors of Aiolos Bio?
Aiolos Bio's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
Who are Aiolos Bio's investors?
Aiolos Bio has 6 investors. Key investors include RA Capital, GSK, Atlas Venture, Bain Capital Life Sciences, and Forbion.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.